Eberhard Schulz

Showing 1-3 of 3 articles

Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study

Brugaletta S, Gori T, Tousek P, Gomez-Lara J, Pinar E, Ortega-Paz L, Schulz E, Kocka V, Münzel T, Cequier A, Buono A, Serruys PW, Sabaté M

March 20, 2020 | 10.4244/EIJ-D-19-00773

Interventions for valvular disease

Incidence and in-hospital safety outcomes of patients undergoing percutaneous mitral valve edge-to-edge repair using MitraClip: five-year German national patient sample including 13,575 implants

von Bardeleben R, Hobohm L, Kreidel F, Ostad MA, Schulz E, Konstantinides S, Lankeit M, Feldman T, Münzel T, Keller K

April 16, 2019 | 10.4244/EIJ-D-18-00961

Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes

Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, Münzel T

January 20, 2014 | 10.4244/EIJV9I9A176

1

Latest news

Lipid-lowering therapy and PCI; thin vs thick stents; mini focus on STEMI; and more…

Outcomes of transcatheter tricuspid valve intervention by right ventricular function

Florian Schlotter et al.

How to eliminate mitral regurgitation definitively: the eternal dilemma?

Thomas Modine et al.

EBC 15th consensus document - Watch the Chat!

Relive the 2nd edition

New update: EXAMINATION 10 years, BIONYX 2 years, SAFE A, MASH and more

(Thanks to the support of Biotronik)

To be better among the best: a difficult task

Antonio Colombo et al.

New JAA's: Calcification of PAD by OFDI and IVUS, Simultaneous PTVR reversing right-left shunts following PMVR?...

Valvular disease